Denali Therapeutics Inc. (DNLI) PT Raised to $105 at H.C. Wainwright
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $25.54 +1.07%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 12 | New: 9
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 12 | New: 9
Join SI Premium – FREE
H.C. Wainwright analyst Andrew Fein raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $105.00 (from $95.00) while maintaining a Buy rating.
You May Also Be Interested In
- Brinker Int'l (EAT) PT Raised to $260 at DA Davidson, Neutral Rating Maintained
- Everus (ECG) PT Lowered to $152 at Cantor Fitzgerald
- Jumia Technologies (JMIA) PT Lowered to $12 at Craig-Hallum
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
